A definitive or thorough phase 1 QT ECG trial as a requirement for drug safety assessment

Haverkamp, 2000, The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: Clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology, Cardiovasc Res, 47, 219, 10.1016/S0008-6363(00)00119-X Morganroth, 1993, Variability of the QTc interval, Am J Cardiol, 72, 26B, 10.1016/0002-9149(93)90037-D 2002, Safety pharmacology studies for assessing the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals 1997, Points to Consider Health Canada: Draft Guidance “Assessment of the QT prolongation potential of non-antiarrhythmic drugs,” March 15, 2001. Available from: http//www.hc-sh.gc.ca/hpb-dgps/therapeut/htmleng/guidmain.html. 2002 Morganroth, 2001, Focus on issues in measuring and interpreting changes in the QTc interval duration, Eur Heart J Supple, 3, K105, 10.1016/S1520-765X(01)90014-8 Funck-Brentano, 1993, Rate-corrected QT interval, Am J Cardiol, 72, 17B, 10.1016/0002-9149(93)90035-B Morganroth, 1991, Variability of the QT measurement in healthy men, Am J Cardiol, 67, 774, 10.1016/0002-9149(91)90541-R Malik, 2002, Relation between QT and RR intervals is highly individual among healthy subjects, Heart, 87, 220, 10.1136/heart.87.3.220 Pratt, 1996, Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram, Am Heart J, 131, 472, 10.1016/S0002-8703(96)90525-6 Darpö, 2001, Spectrum of drugs prolonging the QT interval and the incidence of torsades de pointes, Eur Heart J, 3, K70, 10.1016/S1520-765X(01)90009-4 Shah, 2002, Drug-induced prolongation of the QT interval: Regulatory dilemmas and implications for approval and labeling of a new chemical entity. Shah RR, Fund Clin Pharmacol, 16, 147, 10.1046/j.1472-8206.2002.00083.x